RadNet (RDNT) Stock Price, News & Analysis

+0.70 (+1.22%)
(As of 11:44 AM ET)
Today's Range
50-Day Range
52-Week Range
37,566 shs
Average Volume
516,511 shs
Market Capitalization
$4.30 billion
P/E Ratio
Dividend Yield
Price Target

RadNet MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
1.2% Downside
$57.25 Price Target
Short Interest
4.36% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.39mentions of RadNet in the last 14 days
Based on 12 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.59 to $0.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

357th out of 918 stocks

Medical Laboratories Industry

10th out of 20 stocks

RDNT stock logo

About RadNet Stock (NASDAQ:RDNT)

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

RDNT Stock Price History

RDNT Stock News Headlines

Truist Financial Reaffirms "Buy" Rating for RadNet (NASDAQ:RDNT)
RadNet (NASDAQ:RDNT) Cut to "Sell" at
Peeling Back The Layers: Exploring RadNet Through Analyst Insights
RadNet: Q1 Earnings Snapshot
RadNet Q1 2024 Earnings Preview
RadNet, Inc. (RDNT)
See More Headlines
Receive RDNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$3.04 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.62 billion
Cash Flow
$3.33 per share
Book Value
$14.58 per share


Free Float
Market Cap
$4.24 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Howard G. Berger M.D. (Age 78)
    Chairman, President & CEO
    Comp: $5.56M
  • Mr. Mark D. Stolper (Age 53)
    Executive VP & CFO
    Comp: $1.13M
  • Mr. Mital Patel (Age 38)
    Executive VP of Financial Planning & Analysis and Chief Administrative Officer
    Comp: $1.15M
  • Mr. Norman R. HamesMr. Norman R. Hames (Age 68)
    President & COO of Western Operations
    Comp: $1.28M
  • Mr. Stephen M. Forthuber (Age 63)
    President & COO of Eastern Operations
    Comp: $1.3M
  • Ms. Christine Nayoma Gordon (Age 60)
    Senior VP of Operations - Northern California & Director
    Comp: $384.38k
  • Mr. Ranjan Jayanathan (Age 68)
    Executive VP, Chief Information Officer & GM of eRAD - Radiology Information Technology Division
  • Dr. A. Gregory Sorensen M.D. (Age 62)
    Executive VP, Chief Science Officer & Director
  • Ms. Laura Foster BSRT
    MPH, J.D., Senior Vice President of Compliance & Regulatory Affairs
  • Mr. David Jeffrey Katz (Age 59)
    Executive VP, Chief Legal Officer & Corporate Secretary

RDNT Stock Analysis - Frequently Asked Questions

Should I buy or sell RadNet stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RDNT shares.
View RDNT analyst ratings
or view top-rated stocks.

What is RadNet's stock price target for 2024?

4 brokers have issued twelve-month target prices for RadNet's stock. Their RDNT share price targets range from $48.00 to $63.00. On average, they anticipate the company's stock price to reach $57.25 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts price targets for RDNT
or view top-rated stocks among Wall Street analysts.

How have RDNT shares performed in 2024?

RadNet's stock was trading at $34.77 on January 1st, 2024. Since then, RDNT stock has increased by 64.0% and is now trading at $57.01.
View the best growth stocks for 2024 here

When is RadNet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our RDNT earnings forecast

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) released its quarterly earnings results on Wednesday, May, 8th. The medical research company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. The medical research company earned $431.70 million during the quarter, compared to analysts' expectations of $421.72 million. RadNet had a net margin of 1.28% and a trailing twelve-month return on equity of 5.05%. RadNet's revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) earnings per share.

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet Chief Executive Officer Howard G. Berger on Howard G. Berger has an approval rating of 45% among the company's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

Who are RadNet's major shareholders?

RadNet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.23%), Principal Financial Group Inc. (2.11%), Hood River Capital Management LLC (1.45%), Global Alpha Capital Management Ltd. (1.38%), Edmond DE Rothschild Holding S.A. (1.19%) and Clearbridge Investments LLC (0.74%). Insiders that own company stock include Christine Nayoma Gordon, David L Swartz, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends

How do I buy shares of RadNet?

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RDNT) was last updated on 5/20/2024 by Staff

From Our Partners